- Home
- SNTI vs KPTI Comparison
SNTI vs KPTI Comparison
Compare SNTI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- KPTI
- Stock Information
- Founded
- SNTI 2016
- KPTI 2008
- Country
- SNTI United States
- KPTI United States
- Employees
- SNTI N/A
- KPTI N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- KPTI Health Care
- Exchange
- SNTI Nasdaq
- KPTI Nasdaq
- Market Cap
- SNTI 39.6M
- KPTI 44.5M
- IPO Year
- SNTI N/A
- KPTI 2013
- Fundamental
- Price
- SNTI $1.37
- KPTI $6.08
- Analyst Decision
- SNTI Strong Buy
- KPTI Buy
- Analyst Count
- SNTI 2
- KPTI 6
- Target Price
- SNTI $8.50
- KPTI $39.80
- AVG Volume (30 Days)
- SNTI 120.0K
- KPTI 97.1K
- Earning Date
- SNTI 11-13-2025
- KPTI 11-04-2025
- Dividend Yield
- SNTI N/A
- KPTI N/A
- EPS Growth
- SNTI N/A
- KPTI N/A
- EPS
- SNTI N/A
- KPTI N/A
- Revenue
- SNTI N/A
- KPTI $137,269,000.00
- Revenue This Year
- SNTI N/A
- KPTI $3.40
- Revenue Next Year
- SNTI $150.00
- KPTI $9.69
- P/E Ratio
- SNTI N/A
- KPTI N/A
- Revenue Growth
- SNTI N/A
- KPTI N/A
- 52 Week Low
- SNTI $1.26
- KPTI $3.51
- 52 Week High
- SNTI $16.94
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- SNTI 37.01
- KPTI 49.73
- Support Level
- SNTI $1.33
- KPTI $6.15
- Resistance Level
- SNTI $1.39
- KPTI $6.85
- Average True Range (ATR)
- SNTI 0.08
- KPTI 0.51
- MACD
- SNTI 0.01
- KPTI -0.16
- Stochastic Oscillator
- SNTI 31.43
- KPTI 16.10
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.